Novo Nordisk AS (WBO:NNO2) Total Deposits


WBO:NNO2 Novo Nordisk AS WBO:NNO2
71 GF Score
Price €43.06
GF Value €120.11
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS Total Deposits?

Total Deposits only applies to banks.

WBO:NNO2
71GF Score
Novo Nordisk AS WBO:NNO2
Total Deposits is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novo Nordisk AS (WBO:NNO2) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of €43.06 is trading 64.2% below its estimated GF Value™ of €120.11. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for WBO:NNO2:

  • Total Deposits:
  • GF Value™: €120.11 vs. price of €43.06 (64.2% below fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the WBO:NNO2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
71GF Score

Get the complete analysis for WBO:NNO2

Total Deposits is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€43.06
Price
€120.11
GF Value